Pharmacokinetics of pefloxacin in renal insufficiency

Area of Science:

• Pharmacology
• Nephrology

Background:

• Renal impairment can significantly alter drug pharmacokinetics.
• Understanding pefloxacin behavior in patients with kidney disease is crucial for safe and effective dosing.

Purpose of the Study:

• To investigate the pharmacokinetic profile of pefloxacin in patients with varying degrees of renal failure.
• To assess the impact of renal impairment on pefloxacin distribution, elimination, and metabolite accumulation.
• To evaluate the effectiveness of hemodialysis in pefloxacin removal.

Main Methods:

• Single intravenous infusion of pefloxacin (8 mg/kg) in 15 male patients with renal failure.
• Analysis of drug and metabolite plasma concentrations.
• Comparison of pharmacokinetic parameters between mild and severe renal impairment groups.
• Assessment of pefloxacin removal during hemodialysis in 6 anuric subjects.

Main Results:

• No significant differences in pefloxacin distribution or elimination were observed between patients with mild and severe renal impairment.
• Mean volume of distribution (2.03 L/kg) and plasma clearance (121.3 mL/min) were comparable to healthy subjects.
• The active N-desmethylmetabolite did not accumulate in severe renal failure, with an elimination half-life approximately twice that of pefloxacin.
• Hemodialysis showed poor efficacy in removing pefloxacin.

Conclusions:

• Peffloxacin exhibits predictable pharmacokinetics in patients with renal impairment, suggesting dose adjustments may not be necessary based solely on renal function.
• The N-desmethylmetabolite's kinetics are influenced by renal function but do not lead to significant accumulation.
• Hemodialysis is not an effective method for clearing pefloxacin from the body.